Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics announced today it has expanded its collaboration with AstraZeneca and Merck to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer (mCRPC) and germline BRCA mutations who are likely to respond to olaparip (Lynparza).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.